Dyax Corp. has announced financial results for the second quarter ended June 30, 2015.
Recent highlights include:
- Receipt of Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the investigation of DX-2930 for HAE;
- Total revenue for the second quarter of 2015 of $26.4 million, including KALBITOR net sales of $17.8 million
The second quarter 2015 revenues included $17.8 million of KALBITOR net sales, as compared to $16.6 million for the same period in 2014.
Dyax expects quarterly and annual revenues to fluctuate. For KALBITOR, revenue fluctuations are primarily due to variability in the rate at which individual patients utilize KALBITOR to treat attacks (particularly among patients who experience and treat frequent attacks), as well as the timing and amount of distributor demand.
Research and development expenses at Dyax are not least related to the DX-2930 development program, together with other research programs, and KALBITOR medical support and post-marketing requirements.